Results 91 to 100 of about 211,753 (383)

The knowledge, attitude and behaviours of nurses about pharmacovigilance, adverse drug reaction and adverse event reporting in a state hospital

İstanbul Kuzey Klinikleri, 2015
OBJECTIVE: With the use of any drug comes the possibility of unintended consequences which when harmful are referred to as adverse drug reactions (ADRs).
F. Vural, Seval Çiftçi, B. Vural
semanticscholar   +1 more source

Combining antibody conjugates with cytotoxic and immune‐stimulating payloads maximizes anti‐cancer activity

Molecular Oncology, EarlyView.
Methods to improve antibody–drug conjugate (ADC) treatment durability in cancer therapy are needed. We utilized ADCs and immune‐stimulating antibody conjugates (ISACs), which are made from two non‐competitive antibodies, to enhance the entry of toxic payloads into cancer cells and deliver immunostimulatory agents into immune cells.
Tiexin Wang, Dong Jun Koo, Peter M. Tessier, Greg M. Thurber   +3 more
wiley   +1 more source

The PharmWatch programme: challenges to engaging the community pharmacists in Jamaica

Pharmacy Practice, 2008
In February 2006, there was a renewed effort to encourage reporting of adverse drug reactions (ADRs) in Jamaica. It involved renaming the process the “PharmWatch” programme and revising the reporting form.Objectives: The aims of this study were to assess
Gossell-Williams M, Adebayo SA
doaj  

Antiviral treatment for Bell's palsy (idiopathic facial paralysis) [PDF]

, 2009
BACKGROUND: Antiviral agents against herpes simplex virus are widely used in the treatment of idiopathic facial paralysis (Bell's palsy), but their effectiveness is uncertain. Significant morbidity can be associated with severe cases.
Abiko, Adour, Adour KK Swanson, Ahangar, Allen, Allen, Antunes, Aquino, Axelsson, Bateman, Brandenberg, Chen, Diego, Egger, Engström, Goudakos, Hato, Hato, Hernández, House, Hultcranzt, Ibarrondo, Inanli, Katusic, Kawaguchi, May, McCormick, Morgan, Morgenlander, Murakami, Petruzelli, Pietersen, Pietersen, Ramos Macias, Ross, Rowlands, Roy, Salinas, Sipe, Stjernquist-Desatnik, Sugita, Sullivan, Takasu, Theil, Wolf, Yanagihara, Yeo, Zhou   +47 more
core   +3 more sources

Dammarenediol II enhances etoposide‐induced apoptosis by targeting O‐GlcNAc transferase and Akt/GSK3β/mTOR signaling in liver cancer

Molecular Oncology, EarlyView.
Etoposide induces DNA damage, activating p53‐dependent apoptosis via caspase‐3/7, which cleaves PARP1. Dammarenediol II enhances this apoptotic pathway by suppressing O‐GlcNAc transferase activity, further decreasing O‐GlcNAcylation. The reduction in O‐GlcNAc levels boosts p53‐driven apoptosis and influences the Akt/GSK3β/mTOR signaling pathway ...
Jaehoon Lee, Byung‐Cheol Han, Gi‐Bang Koo, Jihye Park, Mijin Kwon, Young Bin Park, Jae‐Mun Choi, Seung‐Ho Lee, Sangho Roh   +8 more
wiley   +1 more source

A Review of Drug Reaction with Eosinophilia and Systemic Symptoms in the FDA Adverse Event Reporting System (FAERS) [PDF]

, 2021
Sara Bluestein, Roger Yu, Cosby A. Stone, Elizabeth Phillips   +3 more
openalex   +1 more source

Disrupting the Path from Childhood Trauma to Juvenile Justice: An Upstream Health and Justice Approach [PDF]

, 2016
A groundbreaking public health study funded by the U.S. Centers for Disease Control and Prevention (CDC) and the Kaiser Foundation found astoundingly high rates of childhood trauma, including experiences like abuse, neglect, parental substance abuse ...
Cannon, Yael, Hsi, Andrew
core   +2 more sources

What is the epidemiology of medication errors, error-related adverse events and risk factors for errors in adults managed in community care contexts? A systematic review of the international literature [PDF]

, 2018
© Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2018. All rights reserved. No commercial use is permitted unless otherwise expressly granted.Objective To investigate the epidemiology of medication errors and ...
Aljadhey, Hisham, Aloudah, Nouf, Assiri, Ghadah, Grant, Elizabeth, Mahmoud, Mansour, Shebl, Nada, Sheikh, Aziz   +6 more
core   +3 more sources

Basroparib inhibits YAP‐driven cancers by stabilizing angiomotin

Molecular Oncology, EarlyView.
Basroparib, a selective tankyrase inhibitor, suppresses Wnt signaling and attenuates YAP‐driven oncogenic programs by stabilizing angiomotin. It promotes AMOT–YAP complex formation, enforces cytoplasmic YAP sequestration, inhibits YAP/TEAD transcription, and sensitizes YAP‐active cancers, including KRAS‐mutant colorectal cancer, to MEK inhibition.
Young‐Ju Kwon, Dong Young Kim, Yuna Kim, Uk‐Il Kim, Jae‐Sung Kim   +4 more
wiley   +1 more source

Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group. [PDF]

, 2017
Cancer immunotherapy has transformed the treatment of cancer. However, increasing use of immune-based therapies, including the widely used class of agents known as immune checkpoint inhibitors, has exposed a discrete group of immune-related adverse ...
Abdallah, K., Anderson, J., Andrews, S., Arrindell, D., Ballesteros, J., Bingham, C. O., Boyer, J., Brogdon, C., Chen, D., Chonzi, D., Cotarla, I., Cunha, R., Dadu, R., Davies, M., Dawson, M., Diab, A., Dicker, Adam, Eifler, L., Ernstoff, M. S., Ferguson, A., Ferlini, C., Frankel, S., Go, W., Gochett, C., Goldberg, J., Goncalves, P., Goswami, T., Gregory, N., Gulley, J. L., Hamad, L., Hayreh, V., Helie, N., Holmes, W., Hsu, J. Y., Ibrahim, R., Kaufman, H. L., Kim, S., Lacouture, M. E., Lambotte, O., Larocca, C., LeBoeuf, N. R., Lehman, K., Lenihan, D., Ley-Acosta, S., Luke, J., McClure, J., Michelon, E., Nakamura, M., Onofrei, C., Patel, K., Piperdi, B., Puzanov, I., Rasheed, Z., Reshef, D., Riemer, J., Robert, C., Sarkeshik, M., Saylors, A., Schreiber, J., Shafer-Weaver, K., Shannon, V., Sharfman, W., Sharma, R., Sharon, E., Sherry, R., Silk, A. W., Simonson, C., Skondra, D., Suarez-Almazor, M. E., Thomas, C., Thompson, J. A., Trehu, E., Tresnan, D., Turner, M., Wang, Y., Wariabharaj, D., Waxman, I., Wiley, K., Wood, L., Zhang, L., Zheng, P.   +80 more
core   +2 more sources